Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 10:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 3,890 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: no drug Clear all
Recruiting Not applicable Interventional

A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)

NCT06055894
View directory record Official record
Conditions
Multiple Myeloma, Smoldering, Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
Interventions
Omega-3, Curcumin, Probiotic, Whole food, plant-based diet (WFPBD)
Dietary Supplement · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 15, 2026, 10:51 AM EDT
Enrolling by invitation Not applicable Interventional

Comparison of Post-Craniotomy Blood Pressure Targets

NCT07093151
View directory record Official record
Conditions
Intracranial Hemorrhage, Hypertensive, Craniotomy Tumor Removal Surgery
Interventions
Target SBP <160mmHg, Target SBP <140 mmHg
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 15, 2026, 10:51 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma

NCT02661022
View directory record Official record
Conditions
Multiple Myeloma
Interventions
SL-401 7 µg/kg/day, SL-401 9 µg/kg/day
Drug
Lead sponsor
Stemline Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Duarte, California • Boston, Massachusetts • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Oct 15, 2026, 10:51 AM EDT
Terminated Not applicable Interventional Results available

Inhaled Steroids at Discharge After Emergency Department Visits for Children With Uncontrolled Asthma

NCT01881412
View directory record Official record
Conditions
Asthma
Interventions
fluticasone, Standard Asthma Discharge Instructions
Drug · Other
Lead sponsor
Rhode Island Hospital
Other
Eligibility
3 Years to 12 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 18, 2020 · Synced Oct 15, 2026, 10:51 AM EDT
Active, not recruiting Not applicable Interventional

Promoting Preconception Care and Diabetes Self-Management Among Reproductive-Aged Women With Diabetes

NCT04976881
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Electronic Health Record, Primary Health Care, Reproductive Behavior
Interventions
Medication Reconciliation (MedRec) Tool, Provider Alert and Decision Support, PREPSheet, Text Messaging
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 15, 2026, 10:51 AM EDT
Completed Phase 4 Interventional

The Effectiveness of Indinavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients With No Symptoms of Infection

NCT00002179
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine, Zidovudine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • Redwood City, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 15, 2026, 10:51 AM EDT
Completed Not applicable Interventional

Breath Training Exercise for the Reduction of Chronic Dyspnea

NCT01831388
View directory record Official record
Conditions
Chronic Pulmonary Disorder
Interventions
breathing techniques, Self-Administered Baseline and Transition Dyspnea Indexes
Other · Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
19 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Oct 15, 2026, 10:51 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer

NCT06774027
View directory record Official record
Conditions
HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, Metastatic Breast Cancer, HR+ HER2 Breast Cancer, Metastatic Triple Negative Breast Cancers, Metastatic Triple-Negative Breast Carcinoma
Interventions
Specimen collection, Non-Investigational Antibody-Drug Conjugates (ADC), Medical Record Review
Procedure · Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 15, 2026, 10:51 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Impact of Oral Contraceptives on GABA and Neurosteroids

NCT00656318
View directory record Official record
Conditions
Healthy
Interventions
oral contraceptive pill (OCP; OCPs)
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 42 Years · Female only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 25, 2009 · Synced Oct 15, 2026, 10:51 AM EDT
Recruiting Phase 1Phase 2 Interventional

Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers

NCT04645160
View directory record Official record
Conditions
Cholangiocarcinoma, Bile Duct Neoplasm, Biliary Tract Malignancy
Interventions
Tivozanib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 15, 2026, 10:51 AM EDT
Completed Not applicable Interventional

Inpatient Obesity Intervention With Phone Follow-up

NCT01920620
View directory record Official record
Conditions
Obesity
Interventions
Inpatient weight loss counseling, Motivational interviewing and troubleshooting via phone
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Oct 15, 2026, 10:51 AM EDT
Recruiting Not applicable Interventional

Arterial Stiffness and Blood Pressure

NCT06495710
View directory record Official record
Conditions
Hypertension, Vascular Stiffness, Aging
Interventions
Blood pressure treatment algorithm
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
60 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Birmingham, Alabama • Nashville, Tennessee • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 15, 2026, 10:51 AM EDT
Not yet recruiting No phase listed Observational

Molecular Services and EMR-Lab Integration Application (ELIA) for Reducing Healthcare Disparities in Cancer Patients

NCT06090513
View directory record Official record
Conditions
Advanced Cancer, Solid Tumor, Adult, Myeloid Malignancy
Interventions
Comprehensive Genomic Profile testing; ELIA software; Molecular Genetic Pathologist consultation, limited genetic testing or no testing
Combination Product · Diagnostic Test
Lead sponsor
Bien-Willner Physicians Group PA
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Rock Hill, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 15, 2026, 10:51 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC

NCT02805660
View directory record Official record
Conditions
Advanced Cancer
Interventions
Mocetinostat - 50 mg, Mocetinostat - 70 mg, Mocetinostat - 90 mg, Mocetinostat - Recommended Phase 2 Dose (70 mg), Durvalumab - 1500 mg
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
15
States / cities
Mobile, Alabama • Los Angeles, California • Pensacola, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2021 · Synced Oct 15, 2026, 10:51 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Sirolimus Before Surgery in Treating Patients With Advanced Localized Prostate Cancer

NCT00311623
View directory record Official record
Conditions
Prostate Cancer
Interventions
Rapamycin 3mg, Rapamycin 6mg, Radical prostatectomy
Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
3
States / cities
Baltimore, Maryland • Ann Arbor, Michigan • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 22, 2019 · Synced Oct 15, 2026, 10:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cognitive Behavioral Therapy for Anxiety Disorders in Adolescents With Autism

NCT01563003
View directory record Official record
Conditions
Autism, Asperger's Syndrome, Pervasive Developmental Disorder Not Otherwise Specified, Generalized Anxiety Disorder, Social Phobia, Separation Anxiety Disorder, Obsessive-compulsive Disorder
Interventions
Cognitive Behavioral Therapy, Treatment as usual
Other
Lead sponsor
University of South Florida
Other
Eligibility
11 Years to 16 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Apr 17, 2015 · Synced Oct 15, 2026, 10:51 AM EDT
Completed Phase 2 Interventional Results available

Randomized Placebo-Controlled Trial of Atorvastatin in HIV-Positive Patients Not on Antiretroviral Therapy

NCT00367458
View directory record Official record
Conditions
HIV
Interventions
Atorvastatin, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
3
States / cities
San Diego, California • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Oct 15, 2026, 10:51 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Liver and Fat Regulation in Overweight Adolescent Girls

NCT02157974
View directory record Official record
Conditions
Hepatic Steatosis, Polycystic Ovarian Syndrome, Obesity
Interventions
Byetta 5Mcg Pen Injection
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 21 Years · Female only
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Oct 15, 2026, 10:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Microvascular Blood Flow in Sickle Cell Anemia

NCT01566890
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Anemia
Interventions
regadenoson infusion with contrast-enhanced ultrasound, contrast-enhanced ultrasound
Drug · Procedure
Lead sponsor
Versiti Blood Health
Other
Eligibility
18 Years to 70 Years
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2020
U.S. locations
2
States / cities
Chicago, Illinois • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 15, 2026, 10:51 AM EDT
Not yet recruiting Not applicable Interventional

Comparison of Targeting Methods for Transcranial Magnetic Stimulation Treatment of Depression

NCT04730180
View directory record Official record
Conditions
Depression
Interventions
Transcranial Magnetic Simulation, Mixed reality neuronavigation
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 7, 2021 · Synced Oct 15, 2026, 10:51 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius)

NCT05158296
View directory record Official record
Conditions
Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind, Retinal Disease, Eye Diseases, Eye Diseases, Hereditary, Eye Disorders Congenital, Vision Disorders
Interventions
Ultevursen, Sham-procedure
Drug · Other
Lead sponsor
Laboratoires Thea
Industry
Eligibility
12 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
10
States / cities
San Diego, California • San Francisco, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Oct 15, 2026, 10:51 AM EDT
Completed Phase 2 Interventional Results available

31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Parkinson's Disease

NCT03815916
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Gold Nanocrystals
Drug
Lead sponsor
Clene Nanomedicine
Industry
Eligibility
30 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 15, 2026, 10:51 AM EDT
Terminated Phase 2 Interventional Results available

Chemotherapy & Erlotinib in Treating Patients w/ Esophageal or Gastroesophageal Cancer That Cannot Be Removed by Surgery

NCT00539617
View directory record Official record
Conditions
Esophageal Cancer
Interventions
Erlotinib, 5-fluorouracil, Leucovorin, Oxaliplatin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2020 · Synced Oct 15, 2026, 10:51 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Leptin for the Treatment of Hypothalamic Amenorrhea

NCT00130117
View directory record Official record
Conditions
Amenorrhea
Interventions
r-metHuLeptin, Oral Contraceptive Pills (OCPs), Placebo
Drug · Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Oct 15, 2026, 10:51 AM EDT